Clinical Trial

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-05-20; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2021-07-17
Trial Details
NCT Number NCT04900818
Lead Sponsor I-Mab Biopharma US Limited
Collaborators: Bristol-Myers Squibb
Conditions Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Enrollment 330 participants
Start Date 2021-06-29
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-05